Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.61 |
| ▸ | CTSB | P07858 | 4/20 | 0.59 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055182 | 1.00 | CTSL (0.61) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL25243876 | 0.95 | CTSL (0.61) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL25284018 | 0.95 | CTSL (0.61) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL8040518 | 0.94 | CTSL (0.61) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL30001296 | 0.93 | CTSL (0.60) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL25767495 | 0.93 | CTSL (0.52) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL29360471 | 0.93 | CTSL (0.52) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL25767485 | 0.93 | CTSL (0.52) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL24690931 | 0.92 | CTSL (0.60) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL8051930 | 0.92 | CTSL (0.60) | CTSLCAPN1CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-07-06 | — | — | US | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220259145-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2022-08-18 | — | — | US | disclosed |
| WO-2022020711-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259145-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | ACE2, ACE, TMPRSS2 | CTSL 26/4885CAPN1 162/4885CTSB 27/4885 |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | ACE2, ACE, TMPRSS2 | CTSL 26/4885CAPN1 162/4885CTSB 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.